1. Home
  2. SCM vs IMUX Comparison

SCM vs IMUX Comparison

Compare SCM & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stellus Capital Investment Corporation

SCM

Stellus Capital Investment Corporation

HOLD

Current Price

$7.27

Market Cap

244.3M

Sector

Finance

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$13.31

Market Cap

209.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCM
IMUX
Founded
2012
2016
Country
United States
United States
Employees
N/A
66
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
244.3M
209.2M
IPO Year
2012
2013

Fundamental Metrics

Financial Performance
Metric
SCM
IMUX
Price
$7.27
$13.31
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$9.00
$36.00
AVG Volume (30 Days)
250.7K
149.0K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
14.22%
N/A
EPS Growth
N/A
38.00
EPS
0.06
N/A
Revenue
N/A
N/A
Revenue This Year
$0.33
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$117.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.83
$0.51
52 Week High
$14.85
$15.84

Technical Indicators

Market Signals
Indicator
SCM
IMUX
Relative Strength Index (RSI) 35.39 39.44
Support Level $6.83 $11.21
Resistance Level $9.27 $15.82
Average True Range (ATR) 0.34 0.91
MACD -0.07 -0.29
Stochastic Oscillator 23.86 20.18

Price Performance

Historical Comparison
SCM
IMUX

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: